TLR4 and metabolic dysfunction-associated steatohepatitis: Another study indicates that gut microbiota dysbiosis can cause an influx of Tlr4 and Tlr9 agonists into the portal circulation, leading to enhanced hepatic Tnf-α expression that drives NASH progression [2,37].